Interested in Participating in the Pivotal Trial for High Risk PCI? Click here

Established Medicare Reimbursement Procedure code 37.68: Insertion of a percutaneous heart assist device Proactive reimbursement technical support including sample letters, codes, contacts, and case studies * Average of DRG 104, 216, 217, 218. Reimbursement varies by geography.

• Impella Brochure
• Clinical Trial Reimbursement Guidelines*
• Clinical Experience Report

* Information provided for clinical trial purposes only

The Impella® is an Investigational Device limited by U.S. Federal Law solely for Investigational Use in the United States..

The Impella 2.5 is a minimally invasive, percutaneous ventricular assist device that allows the heart to rest and recover by:

• Actively unloading the left ventricle
• Reducing myocardial workload and oxygen consumption
• Increasing cardiac output and coronary and end-organ perfusion

The Impella 2.5 can be inserted into the left ventricle in a Cath Lab via a standard guidewire through the femoral artery, into the ascending aorta, across the valve and into the left ventricle.The tip of the catheter contains a “pigtail” that crosses the patient’s heart valve and rests in the left ventricle, generating flows up to 2.5 L/min.

The Impella 2.5 has been used to support over 500 patients during high-risk PCI, post PCI, and with AMI with low cardiac output. Results from these experiences include:

• Ease of Placement and Operation
• Hemocompatible
• No compromise to valve function
• Improved limb and tissue perfusion
• Low Hemolysis, bleeding, and stroke rates
• Restored Hemodynamics
• Improved outcomes
• Unloading effect on the left ventricle